Summit Therapeutics Inc.
SMMT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SMMT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SMMT
Summit Therapeutics Inc. is a pre-revenue biopharmaceutical company focused on developing ivonescimab, a bispecific antibody, for oncology indications, with a lead program in non-small cell lung cancer (NSCLC).
Key risk: Pre-revenue and net losses
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 20 clinical trials · 5 catalysts for Summit Therapeutics Inc..
Summit Therapeutics Inc. is a pre-revenue biopharmaceutical company focused on developing ivonescimab, a bispecific antibody, for oncology indications, with a lead program in non-small cell lung cancer (NSCLC).
- Lead product candidate is ivonescimab (SMT112), a bispecific antibody targeting PD-1 and VEGF, being developed in NSCLC and colorectal cancer (CRC) [sec_mda · as of 2026-02-23].
- Cash and equivalents were $419.7M as of 2026-06-30, with a net loss of $215.7M for the six months ended June 30, 2026 [sec].
- Research and development expenses increased by $371.9M in 2025 versus 2024, driven by stock-based compensation and investment in ivonescimab clinical trials [sec_mda · as of 2026-02-23].
- The company has a clinical trial collaboration with GSK to evaluate ivonescimab in combination with GSK's B7-H3 targeting ADC, risvutatug rezetecan, across multiple solid tumors [sec · filed 2026-01-12].
What works
- Ivonescimab is being evaluated in multiple Phase 3 trials across NSCLC and CRC, targeting large market opportunities [sec_mda · as of 2026-02-23].
- The company has a collaboration with GSK to explore combination therapy, potentially expanding the therapeutic utility of ivonescimab [sec · filed 2026-01-12].
- Summit has a cash position of $419.7M as of 2026-06-30, providing runway for ongoing clinical development [sec].
What to weigh
- Summit is a pre-revenue company with no approved products and has incurred significant net losses, including $215.7M in the first half of 2026 [sec].
- The company will need additional funding in the future to support operations, as it expects to finance cash needs through equity, debt, or collaborations [sec_mda · as of 2026-02-23].
- Clinical development of ivonescimab is subject to high costs, regulatory risks, and uncertain timelines, with multiple Phase 3 trials ongoing [sec_mda · as of 2026-02-23].
From the filings
Quoted directly from source documents.
Summit is a pre-revenue biopharmaceutical company focused on oncology.
“We are a pre-revenue biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical n”
SEC filings · April 17, 2026
Ivonescimab is being developed in NSCLC and CRC.
“The Company is developing ivonescimab in NSCLC and CRC, specifically conducting Phase III clinical trials in the following proposed indications: (a) ivonescimab combined with chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a third-generation EGFR TKI ("HARMONi"); (b) ivonescimab combined with chemotherapy in patients with first-line metastatic NSCLC (including separate statistical analyses planned for patients with squamous NSCLC and non-squamous NSCLC) ("HA”
SEC MD&A · February 23, 2026
Summit has a clinical trial collaboration with GSK.
“the Company issued a press release announcing a clinical trial collaboration with GSK plc ("GSK") to evaluate ivonescimab in combination with GSK's risvutatug rezetecan (also known as GSK'227), GSK's novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC).”
SEC filings · January 12, 2026
Summit's cash position was approximately $710 million as of January 2026.
“the preliminary unaudited balance of cash, cash equivalents, and short-term investments of Summit Therapeutics Inc. (the "Company") was approximately $710 million.”
SEC filings · January 12, 2026
Catalyst timeline
- 2026-11-14 · PDUFA · ivonescimab — PDUFA date for ivonescimab, a regulatory decision point for potential approval.
- 2026-12-31 · Phase3_Topline · ak112 — Phase 3 topline data for AK112 combined with pemetrexed in NSCLC, a key efficacy readout.
- 2029-06-01 · Phase3_Topline · ivonescimab — Phase 3 topline data for ivonescimab versus pembrolizumab, a head-to-head comparison.
- 2029-11-30 · Phase3_Topline · ivonescimab — Phase 3 topline data for ivonescimab in a randomized, active-controlled study.
- 2029-12-31 · Phase3_Topline · ivonescimab — Phase 3 topline data for ivonescimab combined with chemotherapy versus standard of care.
Risks & what to watch (4)›
Key risks
- Pre-revenue and net losses — Summit has no approved products and reported a net loss of $215.7M for H1 2026, with accumulated deficits [sec].
- Need for future funding — The company expects to need additional capital to fund operations, which may not be available on favorable terms [sec_mda · as of 2026-02-23].
- Clinical and regulatory risk — Ivonescimab is in Phase 3 trials; failure or delays could materially impact the company's prospects [sec_mda · as of 2026-02-23].
- Dependence on single asset — Summit's pipeline is heavily focused on ivonescimab, with limited diversification [sec_mda · as of 2026-02-23].
What to watch
- PDUFA date for ivonescimab on 2026-11-14, a key regulatory milestone [catalyst].
- Phase 3 topline data for ivonescimab in NSCLC (HARMONi) expected by end of 2026 [catalyst].
- Progress of the GSK collaboration and any updates on combination trial data [sec · filed 2026-01-12].
- Cash burn rate and any future financing activities, given the $419.7M cash position as of 2026-06-30 [sec].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Summit Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Summit Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
14.6 months
D/E 0.19 · 0% dilution
Lead: Phase 3
1 candidate
5 upcoming, next in ~76d
6 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
226
Total value held
$2.21B
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 36,391,063 | $690.0M |
| vanguard capital management llc | 11,423,604 | $216.6M |
| fmr llc | 10,853,199 | $205.8M |
| blackrock, inc. | 9,653,758 | $183.0M |
| state street corp | 7,028,160 | $133.3M |
| vanguard portfolio management llc | 5,233,252 | $99.2M |
| geode capital management, llc | 3,315,854 | $62.9M |
| susquehanna international group, llp | 2,410,733 | $45.7M |
| d. e. shaw & co., inc. | 2,242,229 | $42.5M |
| morgan stanley | 1,650,591 | $31.3M |
Showing top 10 of 226 institutional holders of Summit Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 21.6%
- Days to cover
- 7.6
- Shares short
- 29,194,577
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SMMT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Summit Therapeutics Inc.?
Summit Therapeutics Inc. is a pre-revenue biopharmaceutical company focused on developing ivonescimab, a bispecific antibody, for oncology indications, with a lead program in non-small cell lung cancer (NSCLC).
What is Summit Therapeutics Inc.'s lead drug candidate?
Summit Therapeutics Inc.'s most advanced tracked candidate is ivonescimab (Phase 3) for Non-Small Cell Lung Cancer.
What is Summit Therapeutics Inc.'s next catalyst?
Summit Therapeutics Inc.'s next tracked catalyst is a PDUFA event — "PDUFA Date: ivonescimab" — expected November 14, 2026.
Who is the CEO of Summit Therapeutics Inc.?
Mr. Robert W. Duggan is the chief executive officer of Summit Therapeutics Inc. (SMMT).
Where is Summit Therapeutics Inc. headquartered?
Summit Therapeutics Inc. (SMMT) is headquartered in Miami, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.